GlassScriptPhysician profile
Jesse David Sheffield
NPI 1265408298
$2,818.00
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $402 · 2021: $464 · 2022: $226 · 2023: $806 · 2024: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $424.54 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $400.77 | 2019-2023 | Rybelsus, Ozempic |
| Abbvie INC. | $338.95 | 2021-2024 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $297.59 | 2019-2024 | Jardiance, Mounjaro, Trulicity |
| Supernus Pharmaceuticals, INC. | $151.11 | 2021-2024 | Qelbree |
| Pfizer INC. | $142.71 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $116.93 | 2019-2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.07 | 2021-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $87.92 | 2019-2021 | |
| Allergan, INC. | $86.13 | 2020 | |
| Angiodynamics, INC. | $72.84 | 2021 | |
| Merck Sharp & Dohme LLC | $72.31 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.96 | 2019-2022 | |
| Amarin Pharma, INC. | $65.16 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $61.86 | 2019-2024 | Airsupra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $61.73 | 2019-2020 | |
| Corium, LLC | $38.31 | 2022-2023 | Azstarys |
| Dynasplint Systems INC. | $37.09 | 2021 | |
| Abbott Laboratories | $36.40 | 2021 | |
| Genentech USA, INC. | $30.51 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $23.50 | 2020 | |
| Celgene Corporation | $22.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.90 | 2021 | |
| Astellas Pharma US INC | $17.75 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $15.15 | 2022 | |
| Smith+Nephew, INC. | $13.76 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Sheffield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.